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g.2013.0Abstract In Down syndrome (DS), trisomy 21 leads to overexpression of gene coding for speciﬁc
enzymes. This overexpression translates directly into biochemical aberrations that affect multiple
interacting metabolic pathways which culminates in cellular dysfunction and contributes to the
unique pathogenesis of DS. The aim of this study is to evaluate parameters of immune response in
terms of cytokines [tumor necrosis factor-a (TNF-a) and interlukin-2 (IL-2)] together with the quan-
titative expression of cystathionine beta synthase (CBS), whose transsulfuration pathway generates
cysteine and hydrogen sulﬁde (H2S). H2S is known to boost host defense at physiological concentra-
tions and to display cytotoxic activity at higher concentrations. Calcineurin activity (CAN) was also
measured as its dysregulation has been shown to cause immune suppression. Subjects were 60 DS
patients vs. 30 age and socioeconomic matching healthy controls. In their blood, the cytokines:
TNF-a and IL-2, together with CBS and its by product H2S as well as CAN activity, were measured.
Results showed that CBSmRNA relative expression (0.56 ± .06 vs. 0.32 ± .02), plasma H2S
(72 ± 8.5 vs. 50.8 ± 4.1) and TNF-a (8.11 ± .01 vs. 3.6 ± 0.9) were signiﬁcantly higher among
DS patients compared to controls, while CAN (0.27 ± 0.1 vs. 0.45 ± 0.2 units), was signiﬁcantly
decreased in blood of DS patients compared to controls. IL-2 (36.4 ± 2.6 vs. 37.4 ± 0.9) showed
no signiﬁcant difference between DS patients and controls. Accordingly it can be concluded that
excessive synthesis of multiple gene products derived from overexpression of the genes present on
chromosome 21 may be the cause for decreased immunity in DS patients compared to controls.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
The molecular basis for DS is the presence of an extra copy of
chromosome 21, referred to as trisomy 21 (Ts21). Chromo-6868206; fax: +20 37833449.
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5.003some 21 contains 303 genes [1]. The excessive synthesis of mul-
tiple gene products derived from over expression of the genes
present on chromosome 21 is thought to underlie both the dys-
morphic features and the pathogenesis of the neurological,
immunologic, endocrine, and biochemical abnormalities that
are characteristic of DS [2]. Recent studies have reported that
young people with Down syndrome suffer from low-grade sys-
temic inﬂammation [3].
The Down syndrome critical region (DSCR1) protein,
now renamed RCAN1 (‘‘Regulator of Calcineurin’’) [4], is
over-expressed in the brain of Down syndrome fetuses andin Shams University.
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Figure 1 Cystathionine beta synthase mRNA in blood of DS
patients (lanes 1–4) compared to controls (lanes 1–3).
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that the 1.5-fold increase in dosage of RCAN1 destabilizes a
regulatory circuit, responsible for many of the features of
Down syndrome [5]. It is suggested that RCAN1 overexpres-
sion, inhibits CAN [6]. Recently, it has been reported that
the gene RCAN1 contained within the DSCR, acts to prevent
the nuclear occupancy of transcription factors responsible for
CAN expression. CAN plays a critical role in regulating T cell
development and activation [7]. In activated T lymphocytes,
CAN dephosphorylates the nuclear factor of activated T cells
and promotes its translocation into the nucleus and the up-reg-
ulation of early T-lymphocyte genes such as the Th1-cytokine
interleukin IL-2 [8,9].
Situated on DSCR1 is the gene controlling CBS, an enzyme
that catalyzes the ﬁrst of two steps in the transsulfuration path-
way that converts homocysteine into cysteine. A 157% increase
in CBS enzyme activity has been previously documented in indi-
viduals with DS and has been associated with reduced levels of
homocysteine and production of H2S [10]. Physiological func-
tions of endogenous H2S have been found to play an important
role as a signal molecule in regulating cell survival [11]. It ap-
pears paradoxical that, on one side, H2S acts as a physiological
intercellular messenger to stimulate cell growth, and on the
other hand H2S at higher concentration is known to be cyto-
toxic. Proliferating T cells depend on their endogenous capacity
to generate H2S, and this capacity is enhanced by T cell activa-
tion [12]. In addition to this autocrine role, H2Smay have a par-
acrine function in T cell activation at normal concentration.
This idea is supported by the report of increased H2S output
from activated antigen presenting cells [13].
TNF-a is an early and potent pro-inﬂammatory cytokine
that stimulates the inﬂammatory response and is involved in
the apoptosis pathway which is injurious [14]. IL-2 is also a
key factor in multiple processes involved in the survival of T
lymphocytes and in the regulation of T cell responses. It plays
an important role in the regulation of anergy because the aner-
gic CD4+ T cells are characterized by their inability to prolif-
erate and express IL-2 following TCR-speciﬁc stimulation in
the presence of adequate costimulation [15,16]. It has been
proposed that anergy results from TCR activation in the ab-
sence of IL-2 production [17,18].
Accordingly, CAN activity and CBS mRNA expression and
H2S together with the cytokines: TNF-a and IL-2, were mea-
sured in blood ofDSpatients and compared to those of controls.
2. Patients and methods
Patients were 60 Down syndrome cases (33 males and 27 fe-
males). Age ranged from 2 to 15 years (mean 9.3 ± 4.1 years).
Controls were 30 matched healthy normal children (18 males
and 12 females), their age ranged from 2 to 14 years (mean
9.1 ± 4.2 years). DS patients were selected from cases already
diagnosed by chromosomal karyotyping in the genetics unit,
pediatric department, Cairo University. Blood was drawn after
an informed consent of the parents in accordance with the cur-
rent revision of the 1975 Helsinki declaration.
3. Measurement of plasma H2S concentration
Plasma sample (0.1 ml) was added to a test tube containing
0.5 ml of 1% zinc acetate and 2.5 ml of distilled water, then0.5 ml of 20 mmol/L N,N-dimethyl-p-phenylenediaminedihy-
drochloride in 7.2 mol/L HCl and 0.4 ml of 30 mmol/L FeCl3
in 1.2 mol/L HCl were also added to the same test tube for
20 min of incubation at room temperature. The protein in
the plasma was removed by adding 1 ml of 10% trichloroacetic
acid to the solution and centrifuging it. The optical absorbance
of the resulting solution at 670 nm was measured with a spec-
trometer [19].
4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis for CBSmRNA
Phytohemagglutinin stimulated lymphocytes were used for
RNA extraction since unstimulated leukocytes contain no
detectable CBS activity [20]. Total RNA was extracted from
lymphocytes using QIAGEN RNA extraction kit (QIAGEN
Inc., USA). The RNA samples were reverse transcribed using
a blend of Sensiscript and Omniscript reverse transcriptases;
using QIAGEN One step RT-PCR kit (QIAGEN Inc. USA).
The cDNAproduct was ampliﬁed using 2.5 units ofHotStarTaq
DNA polymerase, 1 mmol MgCl2/l, and 0.1 umol of the CBS
primer 50-GGG CAC ACC ATC GAG ATC CTC-30and 50-
AGA GCC TGC CCA GCG TGT C-30 [21]. b-actin primers
were: 50-GTG GGG CGC CCC AGG CAC CA-30; and 50-
CTCCTTAATGTCACGCACGAT TTC-30. Five microlitre
of RT reaction of each cDNA was processed for PCR. Ten
microlitre from each PCR reaction product was separated on
a 2% agarose gel then stained with ethidium bromide. The
appearance of speciﬁc bands at 205 and 540 bp for CBS and
b-actin, respectively, using a 50 bp molecular weight marker,
was evaluated under ultraviolet light and photographed.
5. ELISA IL-2
The amounts of IL-2 in circulating lymphocytes were deter-
mined by a sandwich enzyme linked immunosorbent assay
(ELISA) Predicta IL-2 Kit [22].
TNF-a plasma analysis of the cytokine TNF-a was per-
formed using ELISA R & D kit [23].
5.1. Calcineurin activity
The assay was carried out using the AK-804 BIOMOL
GREEN Quantizyme Assay System (Biomol) Bueno et al. [24].
6. Results
Results showed that calcineurin activity (0.27 ± 0.1 vs.
0.45 ± 0.2 units) was signiﬁcantly decreased among DS pa-
tients compared to controls, while CBSmRNA expression
(0.56 ± .06 vs. 0.32 ± .02) (Fig. 1) and H2S (72 ± 8.5 vs.
50.8 ± 4.1) were signiﬁcantly higher among DS patients com-
pared to controls (Table 1). TNF-a (8.11 ± .01 vs. 3.6 ± 0.9)
was signiﬁcantly higher in blood of DS patients compared to
controls and IL-2 (36.4 ± 2.6 vs. 37.4 ± 0.9) showed no
Table 1 Calcineurin and cystathionine beta synthase in blood
of DS patients.
Down syndrome Controls p
Calcineurin activity 0.27 ± 0.1 units 0.45 ± 0.2 units <0.001
CBSmRNA relative
expression
0.56 ± .06 0.32 ± .02 <0.001
H2S lmol/L 72 ± 8.5 50.8 ± 4.1 <0.001
Table 2 Cytokines in blood of DS patients.
Down syndrome Controls p
TNF 8.11 ± .01 3.6 ± 0.9 <0.001
IL-2 36.4 ± 2.6 37.4 ± 0.9 <0.05
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(36.4 ± 2.6 vs. 37.4 ± 0.9) as shown in Table 2.
7. Discussion
The excessive synthesis of multiple gene products derived from
overexpression of the genes present on chromosome 21 is
thought to underlie both the dysmorphic features and the
pathogenesis of the neurological, immunologic, endocrinal,
and biochemical abnormalities that are characteristic of DS.
The successful management of the clinical problems and un-
ique pharmacological sensitivities of these children is a major
medical challenge and depends on understanding of the unique
metabolic imbalance induced by overexpression of the consti-
tutively expressed genes on chromosome 21 [2].
Results of the present study revealed a signiﬁcant decrease
in calcineurin activity among DS patients compared to con-
trols. The reason for this decrease is attributed to a gene lo-
cated on the region DSCR1 inhibiting calcineurin [2]. It has
been demonstrated that RCAN1 protein is overexpressed in
the brain of Down syndrome fetuses, and interacts physically
and functionally with calcineurin [2]. Overexpression of
RCAN1 and RCAN inhibits calcineurin-dependent gene tran-
scription through the inhibition of its transcription factor
(NAFT). CAN plays a critical role in regulating T cell develop-
ment and activation [7].
There was a signiﬁcant increase in CBSmRNA among DS
patients compared to controls. A 157% increase in CBS en-
zyme activity has been previously documented in individuals
with DS and has been associated with reduced levels of homo-
cysteine and increased level of H2S [25,26]. An increased level
of H2S is known to cause memory and motor function deﬁcits
and is cytoxic to T-cells [27,11].
In the present study there was a signiﬁcant increase in cyto-
kine TNF in DS patients compared to controls. This result
although contradictory to the study of Cetiner et al., who
showed decreased levels in TNF among DS children [28], is
in agreement with previous studies that demonstrated the same
as our results [29,30]. Also in vitro incubated DS blood stimu-
lated with 2.5 · 10 [3] TCID50/ml inﬂuenza A virus showed a
signiﬁcant rise in TNF compared with control children. It has
been assumed that the production of higher levels of pro-
inﬂammatory cytokines (TNF) may be responsible for a more
severe clinical course of viral disease in these children [31],
since TNF is involved in the apoptosis pathway [14].Previous studies are controversial regarding IL-2 produc-
tion by stimulated lymphocytes in DS patients. While a study
showed decreased levels of IL-2 among stimulated lympho-
cytes [32], another study showed increased levels of IL-2
among DS patients compared to controls [33]. Results of the
present study showed no signiﬁcant differences in IL-2 in DS
patients compared to controls. Other studies showed that the
decreased immunity among DS patients is due to decreased
lymphocyte subsets and that the primary immune defect in
DS is in part a depressed number and function of helper T cells
which stimulate Il-2 [34].
Accordingly it can be concluded that excessive synthesis of
multiple gene products derived from overexpression of the
genes present on chromosome 21 may lead to decreased immu-
nity in DS patients compared to controls.
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